chief

Novartis Chief Executive Jimenez to Retire in 2018, Narasimhan Named Successor

Joseph Jimenez (l) will retire next year and be succeeded by Vasant (Vas) Narasimhan, MD.​ BASEL, Switzerland—Novartis AG (NYSE: NVS) chief executive officer Joseph Jimenez, who has led the company since 2010, announced Monday that he plans to step down as CEO in January and retire from the company on Aug. 31, 2018. The pharma company, which also owns Alcon, said its board of directors has appointed Vasant (Vas) Narasimhan, MD, the company’s global head of drug development and chief medical officer, to succeed Jimenez, effective Feb. 1, 2018. Dr. Narasimhan, a member of the company’s executive committee, joined Novartis…


Skinner Promoted to SVP, Chief Provider Relations Officer at New VSP Provider Solutions Division

Michelle Skinner.​ RANCHO CORDOVA, Calif.,— VSP Global announced that Michelle Skinner has been promoted to senior vice president and chief provider relations officer. In this role, Skinner will lead the company’s newly formed doctor-focused division, Provider Solutions, which falls under VSP Global’s Omni-Channel Solutions line of business. Skinner will report directly to the interim CEO of VSP Global, Rob Lynch. Provider Solutions will centralize many provider-facing functions, programs and communications under one umbrella to help better align the doctor experience. Additionally, it will manage and further enhance the VSP Global Premier Program, which connects more VSP patients with VSP network…


Novaliq Names Gabriela Burian, MD, MPH as Chief Medical Officer

HEIDELBERG, Germany—Novaliq GmbH, a Heidelberg-based specialty pharmaceutical company focused on ophthalmology, has appointed Gabriela Burian, MD, MPH, as chief medical officer. She will report to the company’s managing director and CEO, Christian Roesky, PhD. Dr. Burian brings over 25 years of international clinical experience to the company. She is responsible for leading Novaliq’s global clinical development and regulatory efforts, as well as expanding the company’s proprietary ocular therapeutics pipeline. She has deep clinical knowledge and proven leadership in the areas of ophthalmic biomedical research and clinical translation, with specialized expertise in retina diseases. Previously, Dr. Burian held various leadership positions,…


Avedro Appoints Thomas E. Griffin as Chief Financial Officer

Thomas E. Griffin.​ WALTHAM, Mass.—Avedro, a Waltham, Mass.-based ophthalmic pharmaceutical and medical device company specializing in corneal remodeling, has appointed Thomas E. Griffin as chief financial officer. Griffin has more than 25 years of executive management experience at emerging growth medical technology companies. He brings a track record of success, leading both early-stage and commercial companies throughout his career. A veteran finance executive, Griffin has spent his entire career in financial operations at medical technology and biotechnology companies. For 10 years and during the company’s initial public offering, he served as CFO of Entellus Medical, a medical technology company that…


Johnson & Johnson Vision Names Jonathan Talamo as Chief Medical Officer

Dr. Jonathan Talamo.​ NEW BRUNSWICK, N.J.—Johnson Johnson Vision Care has named Dr. Jonathan Talamo as its new chief medical officer (CMO) and worldwide vice president of medical affairs and clinical affairs for Johnson Johnson Vision, which comprises both its vision care and surgical businesses. The move is effective “starting in early July,” the company said in its announcement. Dr. Talamo is an internationally known ophthalmologist with more than 25 years of experience. “Dr. Talamo is recognized in the eye health community as a leader who is on the cutting edge of innovation,” Peter Shen, global head of RD for Johnson…